Ainos Inc
NASDAQ:AIMD
Ainos Inc
Other
Ainos Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Ainos Inc
NASDAQ:AIMD
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
Ainos Inc
Glance View
Ainos, Inc. engages in the discovery and development of pharmaceutical and biotech products. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is researching for the treatment of human disease indications, including Sjogren’s syndrome, thrombocytopenia, and other indications using interferon-alpha. The firm is also developing and manufacturing point-of-care testing rapid test kit products that include diagnostics for COVID-19, pneumonia, vaginal infection and helicobacter pylori bacterial infection. Its business units include Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. Medical Device Division is developing an insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Preventative Medicine Division is focused on SRNA-based therapeutics.